Last reviewed · How we verify
KX-826 1.0% BID — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
KX-826 1.0% BID (KX-826 1.0% BID) — Suzhou Kintor Pharmaceutical Inc,.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| KX-826 1.0% BID TARGET | KX-826 1.0% BID | Suzhou Kintor Pharmaceutical Inc, | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- KX-826 1.0% BID CI watch — RSS
- KX-826 1.0% BID CI watch — Atom
- KX-826 1.0% BID CI watch — JSON
- KX-826 1.0% BID alone — RSS
Cite this brief
Drug Landscape (2026). KX-826 1.0% BID — Competitive Intelligence Brief. https://druglandscape.com/ci/kx-826-1-0-bid. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab